UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 568

Sortiert nach

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

Thrombosis and haemostasis, 2008-02, Vol.99 (2), p.409

2008

Link zum Volltext

Verfügbarkeit prüfen

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

Platelets (Edinburgh), 2006-06, Vol.17 (4), p.209-217

2006

Link zum Volltext

Verfügbarkeit prüfen

Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

The American heart journal, 2009-03, Vol.157 (3), p.562-562.e9

2009

Link zum Volltext

Verfügbarkeit prüfen

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

British journal of clinical pharmacology, 2007-04, Vol.63 (4), p.421-430

2007

Link zum Volltext

Verfügbarkeit prüfen

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humans

Platelets (Edinburgh), 2006-06, Vol.17 (4), p.218-226

2006

Link zum Volltext

Verfügbarkeit prüfen

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

Chest, 1998-11, Vol.114 (5 Suppl), p.445S

1998

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1738-1738

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract A86: A phase 1 study of LY2523355, an Eg5 inhibitor, administered on Days 1, 2, and 3 with or without pegfilgrastim in patients with advanced malignancy (NCT01214629)

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A86-A86

2011

Link zum Volltext

Verfügbarkeit prüfen

Assessment of P2Y 12 inhibition with the point-of-care device Verify Now P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

The American heart journal, 2009, Vol.157 (3), p.562.e1-562.e9

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1439: Cytochrome P450 Genetic Variants Predict Cardiovascular Outcomes following Treatment with Clopidogrel but not with Prasugrel

Circulation (New York, N.Y.), 2008-10, Vol.118 (suppl_18)

2008

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR

Blood, 2005-11, Vol.106 (11), p.278-278

2005

Link zum Volltext

Verfügbarkeit prüfen

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo. Commentary

Journal of the American College of Cardiology, 2008, Vol.52 (24), p.1968-1980

2008

Link zum Volltext

Verfügbarkeit prüfen

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y 12 inhibitor, compared with clopidogrel in healthy humans

British journal of clinical pharmacology, 2007-04, Vol.63 (4), p.421-430

2007

Link zum Volltext

Verfügbarkeit prüfen

Assessment of P2Y12 inhibition with the point-of-care device Verify Now P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

The American heart journal, 2009, Vol.157 (3), p.562.e1-562.e9

2009

Link zum Volltext

Verfügbarkeit prüfen

HEREDITARY ANTITHROMBIN III DEFICIENCY AND PREGNANCY: REPORT OF TWO CASES AND REVIEW OF THE LITERATURE

Obstetrics and gynecology (New York. 1953), 1985-06, Vol.65 (6), p.848-853

1985

Link zum Volltext

Verfügbarkeit prüfen

Quality assurance in hemostasis : The perspective from the college of american pathologists proficiency testing program: Standardization, quality assurance, and emerging diagnostic technologies in hemostasis

Seminars in thrombosis and hemostasis, 2007, Vol.33 (3), p.250-258

2007

Link zum Volltext

Verfügbarkeit prüfen

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor: A single ascending dose study in healthy humans

Platelets (Edinburgh), 2006-01, Vol.17 (4), p.209-217

2006

Link zum Volltext

Verfügbarkeit prüfen

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor: A multiple-dose study in healthy humans

Platelets (Edinburgh), 2006-01, Vol.17 (4), p.218-226

2006

Link zum Volltext

Verfügbarkeit prüfen

External peer review quality assurance testing in von willebrand disease : The recent experience of the United States college of American pathologists proficiency testing program: Laboratory Issues in the Identification and Diagnosis of von Willebrand Disease: On the 80th Anniversary of Erik von Willebrand's Original Publication

Seminars in thrombosis and hemostasis, 2006, Vol.32 (5), p.499-504

2006

Link zum Volltext

Verfügbarkeit prüfen

A method for preficiency testing of small peer groups in the college of American pathologists Coagulation Surveys

Archives of pathology & laboratory medicine (1976), 1999-03, Vol.123 (3), p.199

1999

Link zum Volltext

Verfügbarkeit prüfen

Oral Anticoagulants

Chest, 1998-11, Vol.114 (5), p.445S-469S

1998

Link zum Volltext

Verfügbarkeit prüfen

Phosphoinositide 3-Kinase and p72 Noncovalently Associate with the Low Affinity Fc Receptor on Human Platelets through an Immunoreceptor Tyrosine-based Activation Motif

The Journal of biological chemistry, 1996-05, Vol.271 (18), p.10775

1996

Link zum Volltext

Verfügbarkeit prüfen

Phosphoinositide 3-Kinase and p72 Noncovalently Associate with the Low Affinity Fcγ Receptor on Human Platelets through an Immunoreceptor Tyrosine-based Activation Motif

The Journal of biological chemistry, 1996-05, Vol.271 (18), p.10775-10781

1996

Link zum Volltext

Verfügbarkeit prüfen

Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH

Thrombosis and haemostasis, 1995-10, Vol.74 (4), p.1185

1995

Link zum Volltext

Verfügbarkeit prüfen

PLATELET AGGREGATING FACTOR IN THROMBOCYTOPENIC PURPURA

The Lancet (British edition), 1979-09, Vol.314 (8140), p.463-464

1979

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 568

Suche als RSS-Feed

Aktive Filter

ThemaAged

ThemaScience & Technology

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(494)
Mit Volltextzugriff
(524)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(59)
Social Sciences
(41)
Biological And Medical Sciences
(38)
Medical Sciences
(25)
Female
(22)
Editorials
(19)
Psychology
(17)
Fundamental And Applied Biological Sciences. Psychology
(16)
Male
(15)
Adult
(14)
Studies
(13)
Animals
(11)
Astrophysics
(10)
Adolescent
(9)
Economics
(9)
Human
(9)
Sun
(9)
Child
(8)
Government & Law
(8)
Political Science
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humans

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors

Abstract A86: A phase 1 study of LY2523355, an Eg5 inhibitor, administered on Days 1, 2, and 3 with or without pegfilgrastim in patients with advanced malignancy (NCT01214629)

Assessment of P2Y 12 inhibition with the point-of-care device Verify Now P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

Abstract 1439: Cytochrome P450 Genetic Variants Predict Cardiovascular Outcomes following Treatment with Clopidogrel but not with Prasugrel

A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo. Commentary

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y 12 inhibitor, compared with clopidogrel in healthy humans

Assessment of P2Y12 inhibition with the point-of-care device Verify Now P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

HEREDITARY ANTITHROMBIN III DEFICIENCY AND PREGNANCY: REPORT OF TWO CASES AND REVIEW OF THE LITERATURE

Quality assurance in hemostasis : The perspective from the college of american pathologists proficiency testing program: Standardization, quality assurance, and emerging diagnostic technologies in hemostasis

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor: A single ascending dose study in healthy humans

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y 12 inhibitor: A multiple-dose study in healthy humans

A method for preficiency testing of small peer groups in the college of American pathologists Coagulation Surveys

Oral Anticoagulants

Phosphoinositide 3-Kinase and p72 Noncovalently Associate with the Low Affinity Fc Receptor on Human Platelets through an Immunoreceptor Tyrosine-based Activation Motif

Phosphoinositide 3-Kinase and p72 Noncovalently Associate with the Low Affinity Fcγ Receptor on Human Platelets through an Immunoreceptor Tyrosine-based Activation Motif

Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH

PLATELET AGGREGATING FACTOR IN THROMBOCYTOPENIC PURPURA

Aktive Filter

Suchergebnisse filtern